We assign a fundamental rating of 2 out of 10 to ONTX. ONTX was compared to 191 industry peers in the Pharmaceuticals industry. While ONTX seems to be doing ok healthwise, there are quite some concerns on its profitability. ONTX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

ONTX had negative earnings in the past year.
In the past year ONTX has reported a negative cash flow from operations.

1.2 Ratios

ONTX has a worse Return On Assets (-74.67%) than 69.85% of its industry peers.
Looking at the Return On Equity, with a value of -139.07%, ONTX is doing worse than 67.34% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-74.67%
ROE	-139.07%
ROIC	N/A

ROA(3y)-67.68%

ROA(5y)-81.73%

ROE(3y)-169.29%

ROE(5y)-214.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ONTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ONTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONTX has about the same amout of shares outstanding than it did 1 year ago.
ONTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -25.63, we must say that ONTX is in the distress zone and has some risk of bankruptcy.
ONTX has a Altman-Z score of -25.63. This is amonst the worse of the industry: ONTX underperforms 86.93% of its industry peers.
ONTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-25.63

ROIC/WACCN/A

WACC9.2%

2.3 Liquidity

A Current Ratio of 2.79 indicates that ONTX has no problem at all paying its short term obligations.
With a Current ratio value of 2.79, ONTX perfoms like the industry average, outperforming 44.72% of the companies in the same industry.
ONTX has a Quick Ratio of 2.79. This indicates that ONTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ONTX (2.79) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.79
Quick Ratio	2.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ONTX have decreased strongly by -21.25% in the last year.
Looking at the last year, ONTX shows a decrease in Revenue. The Revenue has decreased by -1.25% in the last year.
The Revenue for ONTX have been decreasing by -21.87% on average. This is quite bad

EPS 1Y (TTM)-21.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.54%

Revenue 1Y (TTM)-1.25%

Revenue growth 3Y-52.75%

Revenue growth 5Y-21.87%

Sales Q2Q%-5%

3.2 Future

The Earnings Per Share is expected to grow by 1.43% on average over the next years.
Based on estimates for the next years, ONTX will show a quite strong growth in Revenue. The Revenue will grow by 12.62% on average per year.

EPS Next Y-7.23%

EPS Next 2Y0.68%

EPS Next 3Y1.19%

EPS Next 5Y1.43%

Revenue Next Year2.54%

Revenue Next 2Y11.27%

Revenue Next 3Y12.62%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONTX. In the last year negative earnings were reported.
Also next year ONTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.